EcoR1 Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

EcoR1 Capital’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200,000	Closed	-$614K	–	88
2022 Q2	$614K	Hold	200,000	–	–	0.02%	73
2022 Q1	$1.39M	Sell	200,000 -1,397,139	-87%	-$13.7M	0.04%	71
2021 Q4	$26.1M	Buy	1,597,139 +1,226,125	+330%	+$14.3M	0.83%	24
2021 Q3	$3.69M	Buy	371,014 +221,014	+147%	+$2.2M	0.13%	47
2021 Q2	$1.5M	Hold	150,000	–	–	0.06%	62
2021 Q1	$1.49M	Buy	+150,000	New	+$1.55M	0.07%	61

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

EcoR1 Capital's PRDS Position: Q3 2022 in Review

EcoR1 Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 200,000 shares — an estimated $614K sold.

EcoR1 Capital first reported a position in PRDS in Q1 2021 and held it in 6 quarters. The position peaked at $26.1M in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

EcoR1 Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
EcoR1 Capital sold 200,000 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $614K.
EcoR1 Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
EcoR1 Capital's Pardes Biosciences, Inc. Common Stock position peaked at $26.1M in Q4 2021.
68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.